← Eichor
Study identifier: NCT06505577 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study

Condition: Mastectomy · Breast Neoplasm Malignant Primary  ·  Sponsor: Incheon St.Mary's Hospital

PhaseN/A
Planned participants600
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

Breast cancer, the most prevalent malignancy among women globally, is increasing in incidence. While non-metastatic breast cancer requires surgery, determining the optimal extent of resection remains challenging. Inadequate resection margins necessitate reoperation, leading to increased psychological stress, costs, and potentially compromised cosmetic outcomes and prognosis. Accurate preoperative assessment of resection extent is crucial and involves various factors, including imaging studies, physical examinations, tumor molecular subtypes, and intraductal carcinoma components. This prospective observational study aims to identify and integrate multiple predictive factors to enhance surgical planning and minimize reoperation rates in breast cancer patients.

This description comes directly from the study's public registry record.

Talk to the study team

Young-Joon Kang, Ph.D.  ·  82 32-280-5179  ·  yjkang.md@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Incheon St. Mary's HospitalIncheon, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06505577